What's Happening?
The National Organization for Rare Disorders (NORD) has announced seven new requests for proposals (RFPs) totaling $452,000 in seed grant funding. These grants are designed to accelerate research for six specific rare diseases: Appendix Cancer/Pseudomyxoma
Peritonei, Peutz-Jeghers syndrome, primary orthostatic tremor, Beckwith-Wiedemann syndrome, alveolar capillary dysplasia, and pheochromocytoma. The funding for these grants was provided by various NORD Member patient organizations and communities associated with these diseases. Applications for these grants will undergo a peer-review adjudication process, led by NORD’s Medical Advisory Committee and Centers of Excellence, which comprises volunteer rare disease medical experts. Since 1989, NORD has awarded over $9 million in research grants to advance scientific discovery for rare diseases that often lack sufficient treatment and research funding.
Why It's Important?
This initiative is crucial because fewer than 5% of the approximately 10,000 known rare diseases currently have an FDA-approved therapy. The high cost of developing prescription medications, often reaching millions of dollars, makes early-stage funding like these seed grants critically important for unlocking progress in rare disease research. NORD, a leading independent, nonpartisan nonprofit, serves over 30 million Americans affected by rare diseases. By partnering with more than 350 disease-specific member patient organizations and 50 designated NORD Rare Disease Centers of Excellence, NORD plays a vital role in advancing care, research, education, and advocacy. These grants directly address the significant unmet medical needs of patients with rare diseases, offering hope for new treatments and improved quality of life.
What's Next?
The next phase involves the submission and peer-review adjudication of grant applications by NORD’s Medical Advisory Committee and Centers of Excellence. Following this rigorous evaluation, the selected research projects will receive funding to commence their work. The outcomes of these early-stage research efforts could potentially lead to significant breakthroughs in understanding the mechanisms of these rare diseases, identifying potential therapeutic targets, and ultimately developing new treatments. Continued collaboration between NORD, patient organizations, and research institutions will be essential to monitor progress and ensure that the research findings are translated into tangible benefits for patients. Future funding rounds and expanded research initiatives are likely as NORD continues its mission.
Beyond the Headlines
The announcement of these seed grants highlights a broader systemic challenge within the healthcare landscape: the disproportionate lack of research and treatment options for rare diseases. While individually rare, collectively, these conditions affect a substantial portion of the U.S. population. NORD's sustained commitment, evidenced by over $9 million in grants since 1989, underscores the critical role of non-profit organizations and patient advocacy groups in filling funding gaps left by traditional pharmaceutical research, which often prioritizes more common diseases due to market size. This effort also fosters a collaborative ecosystem where patient communities directly contribute to and influence the research agenda, ensuring that scientific endeavors are aligned with the most pressing needs of those living with rare conditions. It represents a model for how targeted, community-driven funding can catalyze scientific discovery in underserved medical areas.













